Special Precautions News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cold and Flu Prevention Tips for the Workplace

Here are some practical tips and strategies for flu prevention as well as reducing the risk of cold and flu spread among employees.

Ma healthFostera healthHow flu viruses spreadTransmission routesCold preventionGet sickFlu vaccineSeeking medicalHigh risk groupsSpecial precautionsHealth conscious workplaceRespiratory infectionReward healthyPhysical healthCan we encourage employeesBest practices

Takeda Pharmaceutical (TAK) Announces Publication of Phase 4 Vedolizumab Study Results

Takeda Pharmaceutical (TAK) Announces Publication of Phase 4 Vedolizumab Study Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJun saitoMegan ostrowerMarcelo freireJohn cunninghamSimon travisFachinformation entyvioTakeda pharmaceutical company limitedKennedy instituteEuropean unionInternational mediaGlobal medical affairsExchange commissionUniversity of oxfordTakeda pharmaceutical companyNew england journal

Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine

−The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus. | March 30, 2023

United statesSimon travisJohn cunninghamFachinformation entyvioMarcelo freireExchange commissionGlobal medical affairsEuropean unionKennedy instituteUniversity of oxfordTakeda pharmaceutical company limitedNew england journalProfessor simon travisTranslational gastroenterology unitVice presidentTherapeutic area head

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United statesBin chenJohn cunninghamChinwe ukomaduCrohn diseasevedolizumabCancer centerInternational blood marrow transplant researchHematopoietic cell transplant therapy programExchange commissionEuropean unionEuropean medicines agencyTakeda pharmaceutical company limitedYi bin chenHematopoietic cell transplantCell therapy programMass general cancer

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1

United statesBin chenJohn cunninghamJun saitoCancer centerInternational blood marrow transplant researchHematopoietic cell transplant therapy programExchange commissionEuropean unionEuropean medicines agencyTakeda pharmaceutical company limitedMet its primary efficacy endpointClinically meaningful intestinalFree survivalNew safety signals were seenVedolizumab compared